Michael Brown - Regeneron Pharmaceuticals Independent Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Earning Report: February 6, 2020  

Dr. Michael S. Brown, M.D., is an Independent Director of the Company. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, and is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics, at The University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Drs. Brown and Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988. Dr. Brown is a member of the National Academy of Sciences, the National Academy of Medicine, and Foreign Member of the Royal Society of London. Dr. Brown retired as a member of the board of directors of Pfizer Inc. in 2012.
Age: 77  Director Since 1991  Ph.D    
914 847-7000  www.regeneron.com
Brown distinguished scientific and academic background, including his receipt of the Nobel Prize for Physiology or Medicine in 1985, and his significant industry experience gained through his service on the board of directors of the Company and of a leading pharmaceutical company, led to the board to conclude that Dr. Brown should serve as a director.

Michael Brown Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 23.16 % which means that it generated profit of $23.16 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 31.86 % meaning that it created $31.86 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Theodore SamuelsPerrigo Company Plc
Hans HaslerDr Reddys Laboratories Ltd
Jacqualyn FousePerrigo Company Plc
Lloyd CarneyVertex Pharmaceuticals Incorpor
Frank DAmelioZoetis
Jeffrey SmithPerrigo Company Plc
Ravi BhoothalingamDr Reddys Laboratories Ltd
William SteereZoetis
James KangOrigin Agritech Limited
Anupam PuriDr Reddys Laboratories Ltd
Louise ParentZoetis
Jeffrey KindlerPerrigo Company Plc
Theodore SamuelstoPerrigo Company Plc
Linda RhodesZoetis
Elaine UllianVertex Pharmaceuticals Incorpor
Geoffrey ParkerPerrigo Company Plc
David BullockOrigin Agritech Limited
Paul BisaroZoetis
Terrence KearneyVertex Pharmaceuticals Incorpor
Geoffery MerszeiOrigin Agritech Limited
Prasad MenonDr Reddys Laboratories Ltd

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,674 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Instant Ratings Now


Instant Ratings

Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased few shares of
a day ago
Traded for 55.68
Purchased few shares of
a day ago
Traded for 85.37
Purchased one share of
a day ago
Traded for 209.15
Purchased one share of
a day ago
Traded for 333.5
Purchased few shares of
a day ago
Traded for 59.01
Additionally take a look at Your Equity Center. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.